FdaApplication
BLA 101069
Identifiers
- fda_app_no: BLA101069
Properties
| Property | Value |
|---|---|
| applicant_name | Merck Sharp & Dohme LLC |
| application_type | BLA |
| approval_date | 1971-04-22 |
Revenue by product
M-M-R II
| Period | Revenue |
|---|---|
| Q2 2026 | $592.0M |
| Q1 2026 | $538.0M |
| Q4 2025 | $619.0M |
| Q3 2025 | $684.0M |
| Q2 2025 | $609.0M |
| Q1 2025 | $539.0M |
| Q4 2024 | $594.0M |
| Q3 2024 | $703.0M |
| Q2 2024 | $617.0M |
| Q1 2024 | $570.0M |
| Q4 2023 | $545.0M |
| Q3 2023 | $713.0M |
| Q2 2023 | $582.0M |
| Q1 2023 | $528.0M |
| Q4 2022 | $525.0M |
| Q3 2022 | $668.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| M-M-R II | — | 0.5ML | For Injection |
| M-M-R II | — | 0.5ML | For Injection |
2 products